136 related articles for article (PubMed ID: 9073003)
1. Commercial plasma alpha1-antitrypsin (Prolastin) contains a conformationally inactive, latent component.
Lomas DA; Elliott PR; Carrell RW
Eur Respir J; 1997 Mar; 10(3):672-5. PubMed ID: 9073003
[TBL] [Abstract][Full Text] [Related]
2. Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema.
Elliott PR; Bilton D; Lomas DA
Am J Respir Cell Mol Biol; 1998 May; 18(5):670-4. PubMed ID: 9569237
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of latent alpha 1-antitrypsin.
Lomas DA; Elliott PR; Chang WS; Wardell MR; Carrell RW
J Biol Chem; 1995 Mar; 270(10):5282-8. PubMed ID: 7890640
[TBL] [Abstract][Full Text] [Related]
4. Osmolytes as modulators of conformational changes in serpins.
Chow MK; Devlin GL; Bottomley SP
Biol Chem; 2001 Nov; 382(11):1593-9. PubMed ID: 11767949
[TBL] [Abstract][Full Text] [Related]
5. Alpha 1-antitrypsin augmentation therapy.
Sandhaus RA
Agents Actions Suppl; 1993; 42():97-102. PubMed ID: 8356934
[TBL] [Abstract][Full Text] [Related]
6. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
7. A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products.
Cowden DI; Fisher GE; Weeks RL
Curr Med Res Opin; 2005 Jun; 21(6):877-83. PubMed ID: 15969888
[TBL] [Abstract][Full Text] [Related]
8. Biochemical comparison of four commercially available human α
Boerema DJ; An B; Gandhi RP; Papineau R; Regnier E; Wilder A; Molitor A; Tang AP; Kee SM
Biologicals; 2017 Nov; 50():63-72. PubMed ID: 28882403
[TBL] [Abstract][Full Text] [Related]
9. Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy.
Kolarich D; Turecek PL; Weber A; Mitterer A; Graninger M; Matthiessen P; Nicolaes GA; Altmann F; Schwarz HP
Transfusion; 2006 Nov; 46(11):1959-77. PubMed ID: 17076852
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough.
Balbi B; Ferrarotti I; Miravitlles M
Eur Respir J; 2016 Jan; 47(1):35-8. PubMed ID: 26721962
[No Abstract] [Full Text] [Related]
11. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.
Nita I; Hollander C; Westin U; Janciauskiene SM
Respir Res; 2005 Jan; 6(1):12. PubMed ID: 15683545
[TBL] [Abstract][Full Text] [Related]
12. [The evolution of the replacement treatment of emphysema due to alpha 1-antitrypsin deficiency].
Manresa F
Arch Bronconeumol; 1995; 31(7):371-2. PubMed ID: 8777536
[No Abstract] [Full Text] [Related]
13. Kinetic instability of the serpin Z alpha1-antitrypsin promotes aggregation.
Knaupp AS; Levina V; Robertson AL; Pearce MC; Bottomley SP
J Mol Biol; 2010 Feb; 396(2):375-83. PubMed ID: 19944704
[TBL] [Abstract][Full Text] [Related]
14. Alpha-1-antitrypsin and other proteinase inhibitors.
Miravitlles M
Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503
[TBL] [Abstract][Full Text] [Related]
15. [Prolastin in the treatment of mild emphysema in patients with alpha 1-protease inhibitor deficiency].
Ulrik CS; Dirksen A; Kok-Jensen A
Ugeskr Laeger; 1992 Mar; 154(12):811-2. PubMed ID: 1553776
[No Abstract] [Full Text] [Related]
16. Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency.
Louie SG; Sclar DA; Gill MA
Ann Pharmacother; 2005 Nov; 39(11):1861-9. PubMed ID: 16219903
[TBL] [Abstract][Full Text] [Related]
17. Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.
Koepke J; Dresel M; Schmid S; Greulich T; Beutel B; Schmeck B; Vogelmeier CF; Janciauskiene S; Koczulla AR
PLoS One; 2015; 10(1):e0117497. PubMed ID: 25635861
[TBL] [Abstract][Full Text] [Related]
18. Alpha-1-antitrypsin replacement therapy: current status.
Abusriwil H; Stockley RA
Curr Opin Pulm Med; 2006 Mar; 12(2):125-31. PubMed ID: 16456382
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.
Stocks JM; Brantly ML; Wang-Smith L; Campos MA; Chapman KR; Kueppers F; Sandhaus RA; Strange C; Turino G
BMC Clin Pharmacol; 2010 Sep; 10():13. PubMed ID: 20920295
[TBL] [Abstract][Full Text] [Related]
20. [Replacement therapy of emphysema caused by alpha 1-antitrypsin deficiency].
Vidal R; Miravitlles M; de Gracia X; Gallego B; Morell F
Med Clin (Barc); 1991 Feb; 96(5):180-2. PubMed ID: 2033989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
